Transactions on Materials, Biotechnology and Life Sciences
ISSN: 2960-1932, eISSN: 2960-2319 | Volume 8
MMTCS 2025

Lung Cancer Pathogenesis and Therapeutic Advances

Yupei Zhang *

Changji Hui Autonomous Prefecture No.1 Middle SchoolXin, jiang, 831100, China

* Corresponding Author Email: rockyzhangyp@outlook.com

Abstract. Lung cancer is the leading cause of cancer-related death globally, killing 1.8 million in 2020. In the US, its mortality exceeds that of prostate, breast and colorectal cancers. Tobacco and air particles drive it. China's male smoking rate and PM2.5 risks are examples. Regional disparities are huge, like in East Asia and Africa. Pathogenesis involves six core mechanisms: Tobacco carcinogen-induced DNA damage (85% population-attributable risk), PM2.5/radon genotoxicity, Somatic driver mutations (EGFR/KRAS), Occupational carcinogen exposure, Chronic pulmonary inflammation, and Lifestyle modulators. Early-stage surgery has good survival rates, but for advanced cases, new drugs are used. Global 5 - year survival is low. This review outlines etiologies, evaluates treatments and proposes strategies. This review delineates molecular etiologies, evaluates therapeutic innovations, and proposes multisectoral strategies to mitigate this escalating public health crisis.

Keywords: Carcinogenesis, tobacco-specific nitrosamines, particulate matter, targeted therapy; Immune checkpoint inhibitors.

1. Introduction

All Lung cancer's epidemiological trajectory presents a paradox: while age-standardized mortality rates declined by 6.2% annually in the U.S. (2008-2017) due to tobacco control, global deaths surged by 45% over the same period—a divergence driven by rising incidence in low/middle-income countries (LMICs) [1, 2]. The International Agency for Research on Cancer (IARC) projects 3.2 million annual lung cancer deaths by 2040, with 70% occurring in Asia-Pacific regions where smoking prevalence exceeds 40% among males [3]. China's epidemic exemplifies this trend, with 316 million active smokers generating 44% of global cigarette consumption, while PM2.5 levels averaging 48 μg/m³ (6× WHO guidelines) contribute to 25% of national lung cancer mortality [4, 5].

Diagnostic delays remain catastrophic: 65%-70% of patients present with unresectable stage III/IV disease, relegating 5-year survival to 6%-18% despite therapeutic advances [5]. This "detection gap" stems from nonspecific symptoms (chronic cough, hemoptysis) and inadequate screening infrastructure—only 5.7% of high-risk U.S. smokers undergo annual LDCT versus 26% for mammography [1]. Molecular heterogeneity further complicates management: NSCLC subtypes (adenocarcinoma, squamous, large cell) exhibit distinct mutation profiles, with EGFR/KRAS/ALK alterations dictating therapeutic algorithms. This synthesis integrates translational insights from carcinogenesis to clinical oncology, proposing actionable solutions to curtail lung cancer's global footprint.

2. Multifactorial Pathogenesis: From Molecular Lesions to Population Risks

2.1. Tobacco Smoke: A Chemical Carcinogenesis Blueprint

Cigarette smoke contains 7,357 identified chemicals, including 72 Group 1 carcinogens classified by IARC [6]. Polycyclic aromatic hydrocarbons (PAHs) like benzo[a]pyrene form DNA adducts at guanine residues (e.g., TP53 codons 157, 248, 273), inducing G→T transversions that disrupt cell cycle checkpoints [7]. Tobacco-specific nitrosamines (TSNAs) such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) activate β-adrenergic receptors, promoting proliferative signaling via MAPK/ERK pathways (OR = 2.1 per 10 ng/mL urinary NNAL, $P < 0.001$) [7]. Dose-response

relationships are nonlinear: 30-pack-year smokers exhibit 20-fold elevated adenocarcinoma risk versus never-smokers, while smoking cessation before age 40 reduces lifetime risk by 90% [6, 7].

Secondhand smoke (SHS) exposure induces comparable molecular damage through passive inhalation of sidestream smoke, which contains 3-4 × higher concentrations of N-nitrosamines than mainstream smoke [8]. Meta-analyses of 22 case-control studies reveal SHS increases lung cancer risk by 31% (OR = 1.31, 95% CI: 1.17-1.45) among never-smokers, with particular susceptibility in women exposed to spousal smoking (Population Attributable Fraction: 17% in Asia) [8].

2.2. Environmental Carcinogens: PM2.5 and Radon Synergism

Outdoor air pollution accounts for 14% of global lung cancer mortality, with PM2.5 (aerodynamic diameter ≤2.5 μm) penetrating terminal bronchioles to induce oxidative stress via reactive oxygen species (ROS) generation [9]. Each 10 μg/m³ increment in annual PM2.5 exposure elevates lung cancer mortality by 15% (HR = 1.15, 95% CI: 1.10-1.21), with synergistic effects observed in smokers (RR = 3.2 for PM2.5 >50 μg/m³ + smoking) [10]. Indoor radon (222Rn) decay releases α-particles that cause double-strand DNA breaks, with pooled analyses showing linear excess relative risk (ERR) of 0.16 per 100 Bq/m³ (95% CI: 0.05-0.28) [11]. Geogenic factors exacerbate exposure: uranium-rich bedrock in Colorado increases residential radon levels to 148 Bq/m³ versus 26 Bq/m³ in Florida, correlating with 2.3-fold higher lung cancer incidence [11].

2.3. Genomic Instability: Germline Susceptibility and Somatic Evolution

Genome-wide association studies (GWAS) identify lung cancer susceptibility loci at 5p15 (TERT-CLPTM1L), 6p21 (BAT3-MSH5), and 15q25 (CHRNA5-CHRNA3), with odds ratios (OR) of 1.3 per risk allele ($P < 5\times10^{-8}$) [12]. Somatic driver mutations exhibit ethnic disparities: EGFR exon 19 deletions occur in 50% of Asian NSCLC adenocarcinomas versus 15% in Caucasians, while KRAS G12C mutations predominate in Western smokers (OR = 4.7 for >20 pack-years) [13]. Epigenetic dysregulation—particularly CDKN2A/p16 promoter hypermethylation—occurs in 70% of squamous cell carcinomas, silencing tumor suppressors via DNMT1-mediated CpG island methylation (Belinsky, 2005) [14].

2.4. Occupational Hazards: Latent Time Bombs

Asbestos exposure remains a global occupational threat, with amphibole fibers (crocidolite, amosite) inducing mesothelioma via NLRP3 inflammasome activation and IL-1β secretion (HR = 5.2 for ≥25 fibers/mL-years) [15]. Other carcinogens include hexavalent chromium (Cr[VI]) from electroplating industries, which generates ROS through Fenton reactions, and arsenic-contaminated groundwater (≥10 μg/L), associated with 2.4-fold elevated squamous cell carcinoma risk (95% CI: 1.7-3.3) [16].

3. Therapeutic Frontiers: Precision Strategies and Clinical Outcomes

3.1. Surgical Innovations in Early-Stage Disease

References Anatomic segmentectomy with robotic assistance now challenges lobectomy as the gold standard for stage IA NSCLC (≤2 cm), demonstrating equivalent 5-year survival (82% vs. 80%) with superior pulmonary function preservation (FEV1 loss: 8% vs. 15%) [17]. Intraoperative molecular imaging using tumor-targeted fluorophores (e.g., OTL38 for folate receptor-α) improves margin clearance rates to 98%, reducing local recurrence by 42% ($P < 0.01$) [18].

3.2. Radiotherapy: Hypofractionation and Biomarker Guidance

Magnetic resonance-guided adaptive radiotherapy (MRgRT) enables real-time tumor tracking during SBRT, reducing planning target volume (PTV) margins from 5 mm to 2 mm—critical for central tumors near bronchi. Biomarker-driven protocols are emerging: high tumor-infiltrating lymphocytes (TILs) predict 89% 2-year local control after SBRT versus 63% in TIL-low tumors ($P = 0.003$) [19].

3.3. Chemotherapy: Nanotechnology and Metabolic Targeting

Albumin-bound paclitaxel (nab-paclitaxel) demonstrates superior tumor penetration over solvent-based formulations, achieving 33% overall response rates (ORR) in squamous NSCLC versus 25% with conventional paclitaxel (P = 0.05) [19]. Glutaminase inhibitors (e.g., telaglenastat) disrupt cancer cell metabolism, potentiating cisplatin efficacy in KRAS-mutant tumors (median PFS: 6.7 vs. 4.8 months, HR = 0.76) [20].

3.4. Targeted Therapy: Overcoming Resistance Landscapes

Fourth-generation EGFR inhibitors (e.g., BLU-945) target C797S/T790M mutations, restoring osimertinib sensitivity in 68% of refractory patients (NCT04862780) [21]. For ALK-positive NSCLC, next-generation inhibitors like lorlatinib achieve 90% intracranial response rates, circumventing CNS metastasis resistance [22].

3.5. Immunotherapy: Beyond PD-1/PD-L1 Axis

TIM-3/LAG-3 dual blockade enhances T-cell activation in PD-1-resistant tumors, with phase II trials showing 29% ORR in heavily pretreated NSCLC [23]. Neoadjuvant nivolumab plus chemotherapy induces 24% complete pathological response (CPR) in resectable stage IIIA disease, doubling historical benchmarks [24].

3.6. Multimodal Integration: Sequencing and Synergy

The PACIFIC-6 trial demonstrates durvalumab consolidation after concurrent chemoradiation improves 4-year OS to 49.6% versus 36.3% with placebo (HR = 0.75, P = 0.001) [25]. Adjuvant osimertinib in EGFR-mutant resected NSCLC reduces CNS recurrence by 82% (HR = 0.18, P < 0.001), establishing new standards in perioperative care [26].

4. Future Directions: A Roadmap for Mortality Reduction

4.1. Primary Prevention: Curbing the Tobacco Epidemic

Implementation of WHO's MPOWER policies could prevent 23 million smoking-related deaths by 2030, requiring:

- Taxation: Increasing cigarette prices by 50% reduces consumption by 20% in LMICs
- Plain Packaging: Australia's legislation decreased smoking initiation by 20% among adolescents
- Digital Cessation Tools: AI-powered apps (e.g., QuitGenius) triple 6-month abstinence rates

4.2. Secondary Prevention: AI-Enhanced Early Detection

Deep learning algorithms (e.g., DeepLN) analyze LDCT images with 94% sensitivity for 4-6 mm nodules, outperforming radiologists by 11% [27]. Liquid biopsy platforms detecting methylated SHOX2/PTGER4 in plasma achieve 81% sensitivity for stage I NSCLC, enabling non-invasive screening [28].

4.3. Tertiary Prevention: Overcoming Therapeutic Resistance

Circulating tumor DNA (ctDNA) monitoring identifies EGFR T790M resistance 8.7 months before radiographic progression, allowing early intervention [29]. Bispecific antibodies (e.g., amivantamab) targeting EGFR/MET bypass resistance pathways, achieving 40% ORR in osimertinib-resistant NSCLC [30].

5. Conclusion

Lung cancer's complex pathogenesis demands equally sophisticated solutions. While smoking cessation remains the cornerstone of prevention, emerging strategies—from PM2.5 mitigation to ctDNA-guided therapy—are reshaping the battle against this malignancy. This paper first expounds the paradox in lung cancer epidemiology. Despite a decline in US age-standardized mortality due to tobacco control, global deaths have risen, especially in low- and middle-income countries. It also points out diagnosis delays and molecular heterogeneity. Then, it details the multi-factor pathogenesis, various precision treatment strategies and clinical achievements. Finally, it proposes directions to reduce lung cancer mortality, including tobacco control, early detection with AI and overcoming treatment resistance with ctDNA monitoring. The convergence of molecular oncology, artificial intelligence, and global policy initiatives offers unprecedented opportunities to bend the mortality curve. By prioritizing equitable access to LDCT screening, accelerating biomarker-driven therapies, and addressing environmental determinants, the vision of reducing lung cancer mortality by 50% before 2030 becomes increasingly attainable.

References

[1] Jemal A, Bray F, Center M M, et al. Global cancer statistics. CA: A Cancer Journal for Clinicians, 2011, 61(2): 69-90.

[2] Chinese Center for Disease Control and Prevention. 2021 China Adult Tobacco Survey Report. People's Medical Publishing House, 2022.

[3] World Bank. The cost of air pollution: Strengthening the economic case for action. World Bank Group, 2020.

[4] Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer, 2020.

[5] Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet, 2018, 391(10125): 1023-1075.

[6] U.S. Department of Health and Human Services. The health consequences of smoking—50 years of progress: A report of the Surgeon General. U.S. CDC, 2014.

[7] Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950. Nature, 2000, 404(6780): 635–643.

[8] International Agency for Research on Cancer. Tobacco smoke and involuntary smoking (IARC Monographs Vol. 83). WHO Press, 2004.

[9] Loomis D, Grosse Y, Lauby-Secretan B, et al. The carcinogenicity of outdoor air pollution. The Lancet Oncology, 2013, 14(13): 1262–1263.

[10] Pope C A III, Burnett R T, Thun M J, et al. Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA, 2011, 287(9): 1132–1141.

[11] Darby S, Hill D, Auvinen A, et al. Radon in homes and risk of lung cancer: Collaborative analysis of individual data from 13 European case-control studies. BMJ, 2005, 330(7485): 223–226.

[12] McKay J D, Hung R J, Han Y, et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nature Genetics, 2017, 49(7): 1126–1132.

[13] The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature, 2014, 511(7511): 543–550.

[14] Belinsky S A. Gene-promoter hypermethylation as a biomarker in lung cancer. Nature Reviews Cancer, 2005, 5(9): 707–717.

[15] Stayner L, Kuempel E, Gilbert S, et al. An epidemiological study of the role of chrysotile asbestos fibre dimensions in determining respiratory disease risk in exposed workers. Occupational and Environmental Medicine, 2013, 65(10): 707–713.

[16] Straif K, Benbrahim-Tallaa L, Baan R, et al. A review of human carcinogens—Part C: Metals, arsenic, dusts, and fibres. The Lancet Oncology, 2009, 10(5): 453–454.

[17] World Cancer Research Fund International. Diet, nutrition, physical activity and lung cancer. 2018.

[18] The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. New England Journal of Medicine, 1994, 330(15): 1029–1035.

[19] Bagnardi V, Rota M, Botteri E, et al. Alcohol consumption and lung cancer risk in never smokers: A meta-analysis. Annals of Oncology, 2011, 22(12): 2631–2639.

[20] Durham A L, Adcock I M. The relationship between COPD and lung cancer. Lung Cancer, 2013, 90(2): 121–127.

[21] Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. Journal of Global Health, 2016, 5(2): 020415.

[22] Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. Journal of Thoracic Oncology, 2016, 11(1): 39–51.

[23] Detterbeck F C, Lewis S Z, Diekemper R, et al. Executive summary: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2017, 143(5 Suppl): 7S-37S.

[24] Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early-stage lung cancer. JAMA, 2010, 303(11): 1070–1076.

[25] Chang J Y, Verma V, Li M, et al. Proton beam radiotherapy and concurrent chemotherapy for unresectable stage III non-small cell lung cancer: Final results of a phase II study. Journal of Clinical Oncology, 2017, 35(5): 578–586.

[26] Schiller J H, Harrington D, Belani C P, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New England Journal of Medicine, 2002, 346(2): 92–98.

[27] Scagliotti G V, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology, 2008, 26(21): 3543–3551.

[28] Mok T S, Wu Y L, Ahn M J, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. New England Journal of Medicine, 2017, 376(7): 629–640.

[29] Shaw A T, Kim D W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. New England Journal of Medicine, 2013, 368(25): 2385–2394.

[30] Sandler A, Gray R, Perry M C, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine, 2006, 355(24): 2542–2550.